MorphoSys (ETR:MOR) received a €114.00 ($132.56) target price from investment analysts at Goldman Sachs Group in a report released on Friday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the stock. Goldman Sachs Group’s price target would indicate a potential upside of 22.25% from the stock’s current price.
Several other brokerages have also recently issued reports on MOR. Deutsche Bank reaffirmed a “buy” rating and issued a target price on shares of MorphoSys in a report on Wednesday, January 23rd. Royal Bank of Canada set a €65.00 ($75.58) target price on MorphoSys and gave the stock a “sell” rating in a report on Monday, January 28th. Berenberg Bank set a €108.00 ($125.58) target price on MorphoSys and gave the stock a “neutral” rating in a report on Friday, February 15th. JPMorgan Chase & Co. set a €135.00 ($156.98) price objective on MorphoSys and gave the stock a “buy” rating in a research note on Monday, January 28th. Finally, Independent Research set a €96.00 ($111.63) price objective on MorphoSys and gave the stock a “neutral” rating in a research note on Thursday, May 9th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of €100.78 ($117.18).
Shares of MOR stock opened at €93.25 ($108.43) on Friday. MorphoSys has a 12-month low of €76.45 ($88.90) and a 12-month high of €124.90 ($145.23). The company has a current ratio of 7.75, a quick ratio of 7.53 and a debt-to-equity ratio of 8.65. The stock has a market capitalization of $2.94 billion and a PE ratio of -50.16.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Recommended Story: What economic reports are most valuable to investors?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.